v3.26.1
Investment in Loans (Schedule of Commercial Mortgage Loans) (Details) (Details)
$ in Thousands
 6 Months Ended 12 Months Ended
Jun. 30, 2026
USD ($)
loan
Dec. 31, 2025
USD ($)
loan
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Unpaid Principal Balance $ 17,097,672 $ 16,000,731
Unamortized Premium (Discount) (264,552) (245,735)
Loans, at fair value(1)(2) [1],[2] $ 17,874,430 $ 16,640,647
Weighted Average    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Weighted Average Coupon 5.11% 5.21%
Weighted Average Yield 8.60% 8.27%
Weighted average life 5 years 5 years 3 months 10 days
Commercial mortgage loans    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Unpaid Principal Balance $ 680,967 $ 648,592
Unamortized Premium (Discount) (4,873) (7,646)
Investments, at fair value, Cost 676,094 640,946
Gains 273 146
Losses (1,301) (380)
Loans, at fair value(1)(2) $ 675,066 640,712
Number of mortgage loans in process of foreclosure 4  
Mortgage Loans In Process Of Foreclosure, Unpaid Principal Balance $ 25,900  
Commercial mortgage loans | Non-performing    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Unpaid Principal Balance 58,300 64,800
Loans, at fair value(1)(2) $ 53,300 $ 64,100
Number of loans | loan 8 7
Commercial mortgage loans | Weighted Average    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Weighted Average Coupon 8.61% 9.30%
Weighted Average Yield 8.77% 9.15%
Weighted average life 1 year 2 months 8 days 1 year 2 months 4 days
Non-accrual status [Member] | Commercial mortgage loans | Non-performing    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Loans, at fair value(1)(2) $ 53,300 $ 64,100
[1] Ellington Financial Inc.'s Consolidated Balance Sheets include assets and liabilities of variable interest entities it has consolidated. See Note 12 for additional details on Ellington Financial Inc.'s consolidated variable interest entities.
[2] Includes assets pledged as collateral to counterparties. See Note 14 for additional details on the Company's borrowings and related collateral.